Trulicity (Dulaglutide): What It Is, Trial History and Regulatory Status

Evidence tier: Established (FDA-approved; multiple randomized controlled trials).

Trulicity is the brand name under which Eli Lilly and Company markets dulaglutide, a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes. This page summarises what the published literature and the approved product labelling describe, for educational reading only. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication, including whether a GLP-1 receptor agonist has any place in a given medical situation.

What Trulicity (Dulaglutide) Is

Dulaglutide is not a short synthetic peptide of the kind discussed in early-stage pharmacology literature. It is a peptide–protein fusion molecule: two modified GLP-1 analogue peptide chains covalently linked to a modified human immunoglobulin G4 (IgG4) fragment (Fc). The Fc portion greatly slows clearance, which is the structural reason the product is administered once weekly rather than daily. Because of that architecture, dulaglutide is frequently described in plain language as a "GLP-1 peptide drug," but pharmacologically and legally it is an approved prescription product supplied in fixed-dose single-dose pens.

Drug class and pharmacology

Dulaglutide belongs to the GLP-1 receptor agonist class, the same class as exenatide, liraglutide and semaglutide. Agents in this class are studied for their effects on glycated haemoglobin (HbA1c) and body weight; in the head-to-head SUSTAIN 7 trial, researchers reported HbA1c reductions of 1.1 percentage points with dulaglutide 0.75 mg and 1.4 percentage points with dulaglutide 1.5 mg once weekly over 40 weeks, alongside body-weight reductions of 2.3 kg and 3.0 kg respectively (PMID 29397376). Mechanistic work has also looked beyond glucose control: a 2025 preclinical study reported that dulaglutide attenuated hepatic steatosis in obesity through what the investigators characterised as a weight-independent mechanism (PMID 40663700), and an in vitro study reported that dulaglutide alleviated lipopolysaccharide-induced injury in cardiomyocytes (PMID 33817486). Laboratory and animal findings of that kind describe biology in models, not clinical outcomes in people.

Approved indications and approval timeline

Trulicity was first approved by the US Food and Drug Administration in 2014 as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Two subsequent label expansions are relevant to how the product is used today:

• 2020 — cardiovascular indication. The label was expanded to include reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, following the REWIND cardiovascular outcomes trial (PMID 31189511).
• 2020 — higher dose strengths. Additional 3.0 mg and 4.5 mg once-weekly strengths were added to the range of available doses for adults.
• 2022 — paediatric use. Use was extended to children aged 10 years and older with type 2 diabetes, supported by a randomised trial of once-weekly dulaglutide in youths (PMID 35658022).

The labelling states limitations of use rather than broad claims: dulaglutide has not been studied in patients with a history of pancreatitis, and it is not indicated for type 1 diabetes or for weight management. Unlike some other molecules in the class, dulaglutide has never been approved in the United States under a separate brand for chronic weight management.

Trial History: The Pivotal Studies as Published

REWIND: cardiovascular outcomes versus placebo

REWIND was the large cardiovascular outcomes trial for dulaglutide. The study randomised 9,901 adults aged 50 years and older with type 2 diabetes, who had either a previous cardiovascular event or cardiovascular risk factors, to dulaglutide 1.5 mg once weekly or placebo, and followed them for a median of 5.4 years (PMID 31189511). Researchers reported that the primary composite outcome of non-fatal myocardial infarction, non-fatal stroke or death from cardiovascular causes occurred in 594 participants (12.0%) assigned dulaglutide and 663 participants (13.4%) assigned placebo, a hazard ratio of 0.88 (95% CI 0.79–0.99) (PMID 31189511). All-cause mortality was reported in 536 participants (10.8%) receiving dulaglutide versus 592 (12.0%) receiving placebo, a difference the investigators did not describe as statistically significant (PMID 31189511). Notably, a majority of REWIND participants did not have established cardiovascular disease at entry, which distinguished the trial population from several other outcome trials in the class.

A later post hoc analysis of REWIND examined neurodegeneration biomarkers among trial participants, extending the dataset into questions about brain ageing rather than glucose or cardiovascular endpoints (PMID 41988866). Post hoc analyses are exploratory by design and are generally treated as hypothesis-generating rather than confirmatory.

Dulaglutide in youths with type 2 diabetes

The paediatric programme tested once-weekly dulaglutide 0.75 mg and 1.5 mg against placebo over 26 weeks in 154 participants aged 10 to under 18 years who were being treated with lifestyle measures alone or with metformin, with or without basal insulin (PMID 35658022). Researchers reported superior glycaemic control with dulaglutide compared with placebo at 26 weeks, and reported that dulaglutide did not influence body-mass index in this younger population (PMID 35658022). The safety profile reported in the trial was consistent with what had been described in adults, with gastrointestinal events predominating (PMID 35658022).

Head-to-head trials: dulaglutide as the active comparator

Because dulaglutide was an established once-weekly agent, it became the reference comparator in several later phase 3 programmes:

The design and baseline characteristics paper for SURPASS-CVOT described the rationale for choosing dulaglutide 1.5 mg as the comparator: it was an agent with demonstrated cardiovascular benefit, which allowed the trial to test a newer molecule against active therapy rather than placebo (PMID 37758044). Head-to-head superiority on a surrogate endpoint such as HbA1c does not automatically translate into differences in hard clinical outcomes, and the trials above measured different endpoints in different populations.

Smaller and observational literature

Beyond the registration programme, dulaglutide has appeared in smaller comparative and observational work. A randomised pilot study compared dulaglutide with empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes and included exploratory metabolomic and microbiome analyses (PMID 42388875); pilot trials of this size are typically underpowered for clinical endpoints. A population-based cohort study examined dementia incidence among people with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors or dulaglutide (PMID 39186787); observational designs can describe associations but cannot establish that a medicine caused an outcome, and the authors of such analyses generally frame them accordingly.

Adverse Events: What Studies Report

Gastrointestinal events dominate the reported adverse-event profile. In REWIND, researchers reported that gastrointestinal adverse events were more common with dulaglutide 1.5 mg once weekly than with placebo, and gastrointestinal intolerance was the most frequent reason participants stopped study drug (PMID 31189511). In SUSTAIN 7, gastrointestinal disorders — chiefly nausea, vomiting and diarrhoea — were the most frequently reported adverse events in both the dulaglutide and semaglutide groups (PMID 29397376). SURPASS J-mono similarly reported gastrointestinal events as the most common treatment-emergent adverse events across tirzepatide and dulaglutide 0.75 mg groups (PMID 35914543). In the paediatric trial, researchers reported gastrointestinal adverse events more often with dulaglutide than placebo, consistent with adult experience (PMID 35658022).

Label-level warnings. The approved labelling for Trulicity carries a boxed warning regarding the risk of thyroid C-cell tumours, based on findings in rodents; the product is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other labelled warnings and precautions include pancreatitis, hypoglycaemia when used with insulin or insulin secretagogues, hypersensitivity reactions, acute kidney injury (often in the context of dehydration from gastrointestinal effects), acute gallbladder disease, and diabetic retinopathy complications in patients with a history of retinopathy. These are label statements describing identified and potential risks, not predictions about any individual.

Case reports. Isolated case reports also exist in the literature, including a published case of vaginal bleeding attributed by the report's authors to dulaglutide (PMID 37303364). A single case report describes one patient and cannot establish how often an event occurs or whether the drug caused it.

Regulatory Status

Approval and prescription-only supply

Trulicity is an FDA-approved prescription product marketed by Eli Lilly and Company, and it is also authorised in the European Union and many other jurisdictions. It is supplied as prefilled single-dose pens in fixed strengths. Because it is prescription-only, any decision about initiation, dose selection or discontinuation is made by a licensed prescriber in the context of a person's full medical history. Doses referenced on this page — such as the 1.5 mg once-weekly regimen studied in REWIND (PMID 31189511) and the 0.75 mg and 1.5 mg regimens studied in youths (PMID 35658022) — are described as they appeared in those trials and in approved labelling, and are not guidance.

Biologic classification, generics and compounding

Dulaglutide is a protein product rather than a small synthetic peptide, and protein products of that type are regulated in the United States through the biological product pathway. Practically, this means that follow-on competition would come through biosimilar development rather than a conventional generic filing, and that dulaglutide is not a candidate for pharmacy compounding in the way that some small-molecule and short-peptide drugs are. Under US law, compounders generally may not produce copies of commercially available approved drugs, and biological products are outside the scope of the compounding provisions that apply to drugs approved under new drug applications. Media coverage of "compounded GLP-1" products has centred on other molecules in the class, not dulaglutide.

Supply and availability

Availability of GLP-1 receptor agonists has fluctuated across the class in recent years, and specific strengths of individual products have at times been listed as in shortage. Shortage status changes over time and is recorded in the FDA drug shortages database and in manufacturer supply notices, which are the authoritative sources for current status; this page does not track it in real time.

How Dulaglutide Differs From Other Products in the Class

A common point of confusion is the relationship between brand names and active ingredients. Semaglutide is marketed under several brands for different indications, and tirzepatide is marketed under separate brands for diabetes and for weight management. Dulaglutide has only one brand — Trulicity — and no separately branded weight-management version. There is therefore no "sibling product" of dulaglutide with a different indication or dose ladder; the differences that matter are between dulaglutide and other molecules.

• Molecular design. Dulaglutide uses an IgG4 Fc fusion to extend half-life, whereas other once-weekly agents in the class use different half-life-extension strategies.
• Receptor targets. Dulaglutide acts at the GLP-1 receptor alone, while tirzepatide is a dual GIP and GLP-1 receptor agonist — a difference the SURPASS programme was designed to test against dulaglutide as comparator (PMID 37758044).
• Comparative trial results. In direct comparisons, researchers reported greater HbA1c and weight reductions with semaglutide over 40 weeks (PMID 29397376) and with tirzepatide over 52 weeks (PMID 35914543), while the cardiovascular comparison reported non-inferiority of tirzepatide to dulaglutide (PMID 41406444).
• Trial population. REWIND enrolled a population in which most participants had risk factors rather than established cardiovascular disease (PMID 31189511), whereas SURPASS-CVOT required established atherosclerotic cardiovascular disease (PMID 37758044).

Reading This Literature Carefully

Several limitations apply across the dulaglutide evidence base. Randomised trials enrol selected populations under monitoring, so event rates and tolerability in trials may not match those in routine care. Head-to-head trials with open-label designs, such as SUSTAIN 7, can be influenced by participant and investigator awareness of treatment (PMID 29397376). Observational and post hoc analyses generate hypotheses rather than settle them (PMID 39186787), and animal or cell-culture findings describe mechanisms in models (PMID 33817486). Questions about whether a GLP-1 receptor agonist is appropriate, how it interacts with other medicines, or what monitoring applies belong to a conversation with a licensed clinician who can see the whole clinical picture.

PeptideU is not affiliated with or endorsed by Eli Lilly and Company. Trulicity is a trademark of its owner. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

References

• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (Lancet, 2019)
• Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial (The Lancet Diabetes & Endocrinology, 2018)
• Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes (New England Journal of Medicine, 2022)
• Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono) (The Lancet Diabetes & Endocrinology, 2022)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (New England Journal of Medicine, 2025)
• Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia: A Population-Based Cohort Study (Annals of Internal Medicine, 2024)
• Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis (Alzheimer's & Dementia, 2026)
• Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses (Frontiers in Endocrinology, 2026)
• The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism (Diabetes, 2025)
• Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes (ACS Omega, 2021)
• A Case of Dulaglutide-Induced Vaginal Bleed (Cureus, 2023)